Citi Starts Keryx Biopharmaceuticals (KERX) at Sell
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Wall Street stocks end tad lower after hot inflation data ahead of Nvidia earnings
- Nvidia forecasts quarterly revenue above estimates, shares rise
- Oil settles down after choppy session as investors weigh Hormuz talks
- Meta to pay up to $16.68 billion in mass social media settlement
- Anthropic agrees to $45bn cloud computing deal with Nscale - report
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Wall Street ends higher as tech rebounds before Nvidia results
- Six Flags to move headquarters from Charlotte to Arlington, Texas
Brean Capital Reiterates Buy on Keryx Biopharma (KERX) on Potential Catalysts and Improving Sales Dynamics
September 4, 2015 9:02 AM EDTBrean Capital reiterated a Buy rating and $22.00 price target on Keryx Biopharmaceuticals (NASDAQ: KERX) on potential catalysts and improving sales dynamics. Keryx's 50% salesforce increase should make a noticeable impact on revenue, on which analyst Jonathan Aschoff says Keryx will be judged more than its bottom line, for the foreseeable future.
Aschoff commented, "We view the recent Keryx selloff as overdone, especially when considering several factors that we believe have led to a... More
